Global Recombinant Plasma Proteins Market Growth (Status and Outlook) 2023-2029

Global Recombinant Plasma Proteins Market Growth (Status and Outlook) 2023-2029

For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks-

LPI (LP Information)' newest research report, the “Recombinant Plasma Proteins Industry Forecast” looks at past sales and reviews total world Recombinant Plasma Proteins sales in 2022, providing a comprehensive analysis by region and market sector of projected Recombinant Plasma Proteins sales for 2023 through 2029. With Recombinant Plasma Proteins sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Plasma Proteins industry.

This Insight Report provides a comprehensive analysis of the global Recombinant Plasma Proteins landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Plasma Proteins portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Plasma Proteins market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Plasma Proteins and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Plasma Proteins.

The global Recombinant Plasma Proteins market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Recombinant Plasma Proteins is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Recombinant Plasma Proteins is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Recombinant Plasma Proteins is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Recombinant Plasma Proteins players cover CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk, Bayer, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group and Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Plasma Proteins market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others

Segmentation by application
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer

Please note: The report will take approximately 2 business days to prepare and deliver.